Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2FE7T
|
|||
| Drug Name |
Concizumab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Haemophilia A [ICD-11: 3B10.0; ICD-9: 286] | Phase 3 | [1] | |
| Haemophilia B [ICD-11: 3B11.0; ICD-9: 286.1] | Phase 3 | [1] | ||
| Company |
Novo Nordisk Plainsboro, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor pathway inhibitor (TFPI) | Target Info | . | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Blood coagulation | |||
| Pathway Interaction Database | Syndecan-4-mediated signaling events | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Integrated Breast Cancer Pathway | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05135559) Open-label Study Investigating Efficacy, Safety and Pharmacokinetics of Concizumab Prophylaxis in Children Below 12 Years With Haemophilia A or B With or Without Inhibitors. U.S.National Institutes of Health. | |||
| REF 2 | Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 Nov 28;134(22):1973-1982. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.